5-MAPB

Standard Drug Panel Inclusion

5-MAPB (5-(2-Methylaminopropyl)benzofuran) is a benzofuran-class entactogen that is not detected on standard 5-panel or 10-panel immunoassay drug screens. Some MDMA/amphetamine immunoassays may show partial cross-reactivity due to the aminopropyl side chain, but this varies by manufacturer and cannot be relied upon. Extended panels do not typically include benzofuran compounds.

Urine Detection

5-MAPB (5-(2-Methylaminopropyl)benzofuran) can be detected in urine for approximately 2 to 4 days after use. Metabolism involves hepatic oxidation, O-dealkylation, and conjugation. The metabolic pathway has some overlap with MDMA metabolism due to the structural analogy, but the benzofuran ring system produces distinct metabolites. Standard immunoassay screens are unreliable for detecting benzofuran compounds.

Blood and Saliva Detection

Blood detection windows for 5-MAPB (5-(2-Methylaminopropyl)benzofuran) are approximately 12 to 48 hours. Oral fluid detection is possible for 24 to 48 hours. These modalities are used primarily in emergency medicine and forensic toxicology settings rather than routine drug testing.

Hair Follicle Detection

Hair follicle testing for 5-MAPB (5-(2-Methylaminopropyl)benzofuran) requires specialized LC-MS/MS analysis and is not included in standard commercial hair testing panels. Detection in hair is possible for up to 90 days with appropriate analytical methods and reference standards.

Confirmatory Testing

LC-MS/MS is the gold standard for confirming the presence of 5-MAPB (5-(2-Methylaminopropyl)benzofuran). This method can distinguish benzofuran compounds from MDMA, MDA, and other entactogens based on molecular weight, fragmentation patterns, and retention time. GC-MS is also effective. Reference standards are essential for positive identification.

Reagent Testing

Marquis reagent typically produces a dark purple to black color with 5-MAPB (5-(2-Methylaminopropyl)benzofuran), similar to the reaction seen with MDMA and MDA (due to the oxygen-containing ring system). Mecke reagent produces a blue-green to dark blue reaction. Simon's reagent helps differentiate primary amines (5-APB, 6-APDB: negative) from secondary amines (5-MAPB: positive). Mandelin may show an orange-brown color. The combination of reagent responses can narrow identification but cannot conclusively distinguish benzofurans from methylenedioxy compounds.

Test Your Substance

Use a Marquis reagent (expected: orange to black for N-methylated amphetamine/benzofuran compounds) alongside a Simon's reagent, which can differentiate primary from secondary amines — 5-MAPB (secondary amine) should produce a blue color with Simon's, while 5-APB (primary amine) does not.

Dose Guidelines

• Threshold: 40–60 mg |Common: 60–90 mg |Strong: 90–120 mg
• Allow 90–120 minutes for full onset before concluding a dose is insufficient. Many users report a prolonged come-up that leads to premature redosing — the single most common cause of negative experiences with this compound.

Frequency

A minimum 4–6 week interval between uses is the community consensus, with 2–3 months preferred. Serotonin syndrome susceptibility and neurotoxic risk both increase significantly with more frequent dosing.

Physical Care

• Prioritize temperature management — avoid hot, crowded venues; take cooling breaks
• Use electrolyte drinks rather than plain water to prevent hyponatremia
• Avoid mixing with alcohol, other stimulants, or serotonergic medications
• Magnesium glycinate before use to reduce bruxism

Integration

Users consistently report that the emotional content surfaced during 5-MAPB experiences benefits from intentional integration — journaling, conversation, or brief therapeutic reflection after the experience consolidates the empathogenic insights.

Acute Toxicity

The acute toxicity profile of 5-MAPB mirrors that of 5-APB and MDMA: hyperthermia, hyponatremia, serotonin syndrome, and cardiovascular strain represent the primary acute risks. No formal LD50 data are available for humans.

Neurotoxicity

The structural parallel to MDA and 5-APB means that 5-MAPB must be assumed to carry similar serotonergic neurotoxicity potential via reactive metabolite formation. Frequent use at high doses, combined with hyperthermia, is the highest-risk pattern. Conservative dosing frequency (minimum 4–6 weeks, ideally 3 months) and antioxidant supplementation are the standard harm-reduction responses.

Cardiovascular and Cardiac Risks

Sympathomimetic stimulation produces tachycardia and elevated blood pressure. The 5-HT2B agonism raises chronic cardiac risk with repeated use. Individuals with hypertension, arrhythmias, or structural cardiac disease should not use 5-MAPB.

Drug Interactions

• MAOIs — life-threatening serotonin syndrome; absolute contraindication
• SSRIs/SNRIs — blunted effects plus serotonin syndrome risk at overlap
• Stimulants — compounded cardiovascular and neurotoxic risk
• Lithium — unpredictable CNS and seizure risk

• France: 5-MAPB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.

• Germany: 5-MAPB is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.

• Japan: 5-MAPB is a controlled substance in Japan effective August 15th, 2015.

• Luxembourg:** 5-MAPB is not cited in the list of prohibited substances. Therefore, it is still a legal substance.

• Switzerland: 5-MAPB is a controlled substance specifically named under Verzeichnis E.

• United Kingdom: 5-MAPB is a Class B drug.

• United States: 5-MAPB could be considered an analogue of MDA and therefore would be covered under the Federal Analogue Act if intended for human consumption.

• Responsible use

• Designer drug

• Entactogens

• Stimulants

• 5-APB

• 6-APB

• MDAI

• MDA

• MDMA

• 5-MAPB (Wikipedia)

• 5-MAPB (Erowid Vault)

• 5-MAPB (Isomer Design)

• The Big and Dandy 5-MAPB Thread (Bluelight)